Drug Trial Radar · NCT07417189
A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )
Last checked: Nov 19, 2026Latest source record: Mar 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
401
Planned (sponsor's estimate)
Start
Mar 2, 2026
Primary completion
Dec 30, 2028
Study completion Jul 30, 2029
Sponsor
- Lead sponsor
- Abbisko Therapeutics Co, LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human (FIH), exploratory, multicenter, open-label, phase I/II study of ABSK141 in patients with advanced solid tumors to to evaluate safety, tolerability, PK and optimize the dosage.
Conditions
- Solid Tumors, Adult
Interventions
ABSK141-400mgDrug
In the escalation part#patients will first orally receive a single dose of ABSK141 on D-3, followed by a three-day run-in period to assess the PK profile of singledose ABSK141 400mg administration. Thereafter, patients will continuously receive ABSK141 400mg once daily (QD).
ABSK141-Recommended Dose for Expansion (RDE)Drug
In the expansion part# patients will orally receive ABSK141 at the recommended dose for expansion (RDE).patients will continuously receive ABSK141 Recommended Dose for Expansion (RDE) once daily (QD).
ABSK141-800mgDrug
In the escalation part#patients will first orally receive a single dose of ABSK141 on D-3, followed by a three-day run-in period to assess the PK profile of singledose ABSK141 800mg administration. Thereafter, patients will continuously receive ABSK141 800mg once daily (QD).
ABSK141-1200mgDrug
In the escalation part#patients will first orally receive a single dose of ABSK141 on D-3, followed by a three-day run-in period to assess the PK profile of singledose ABSK141 1200mg administration. Thereafter, patients will continuously receive ABSK141 1200mg once daily (QD).
ABSK141-Recommended Phase 2 dose (RP2D)Drug
Phase II #patients will orally receive ABSK141 at the Recommended Phase 2 Dose (RP2D).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of DLTsTime frame: from Run-in to Day28
- Incidence and severity of AEsTime frame: from the time that the patient provides informed consent through and including 30 days after the last administration of ABSK141.
- Incidence and severity of SAEsTime frame: from the time that the patient provides informed consent through and including 30 days after the last administration of ABSK141.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.